These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 29579465)
1. Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Huang X; Tsauo J; Zhao H; Li X J Vasc Interv Radiol; 2018 Apr; 29(4):586. PubMed ID: 29579465 [No Abstract] [Full Text] [Related]
2. Reply to: "Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures". Hickey RM J Vasc Interv Radiol; 2018 Apr; 29(4):587. PubMed ID: 29579466 [No Abstract] [Full Text] [Related]
3. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper. Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818 [TBL] [Abstract][Full Text] [Related]
5. Interventional Oncology: A new pillar for a comprehensive cancer care. Cornelis FH; Lotz JP Presse Med; 2019; 48(7-8 Pt 2):e217-e218. PubMed ID: 31447336 [No Abstract] [Full Text] [Related]
6. [Interventional oncology and immuno-oncology : Status quo]. Helmberger T Radiologe; 2020 Aug; 60(8):681. PubMed ID: 32748259 [No Abstract] [Full Text] [Related]
7. Trends and challenges in immuno-oncology trials. Kiernan B Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitors: a cutting edge in oncology. Jago C Drugs Today (Barc); 2017 Jul; 53(7):399-404. PubMed ID: 28837184 [TBL] [Abstract][Full Text] [Related]
9. Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology. Tocchetti CG; Galdiero MR; Varricchi G J Am Coll Cardiol; 2018 Apr; 71(16):1765-1767. PubMed ID: 29567211 [No Abstract] [Full Text] [Related]
10. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644 [TBL] [Abstract][Full Text] [Related]
11. [The radiologist as the treating physician for cancer: interventional oncology]. van den Bosch MA; Prevoo W; van der Linden EM; Meijerink MR; van Delden OM; Mali WP; Reekers JA Ned Tijdschr Geneeskd; 2009; 153():A532. PubMed ID: 19785894 [TBL] [Abstract][Full Text] [Related]
12. IO + IO = More to Know:: The Uncertain Potential for Combined Interventional and Immuno-Oncology. Brown DB; Agarwal R J Vasc Interv Radiol; 2021 Feb; 32(2):196-197. PubMed ID: 33506768 [No Abstract] [Full Text] [Related]
15. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). Golan T; Milella M; Ackerstein A; Berger R J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151 [TBL] [Abstract][Full Text] [Related]
16. Impact of Interventional Oncology Therapies on Tumor Microenvironment and Strategies to Enhance Their Efficacy. Fan SKY; Li B; Chen Q; Midia M AJR Am J Roentgenol; 2018 Mar; 210(3):648-656. PubMed ID: 29364726 [TBL] [Abstract][Full Text] [Related]